Treatment of respiratory infection by pseudomonas aeruginosa in adult patients within a hospital at home service: Clinical characteristics and analysis of prognostic factors for relapse;Tratamiento de la infección respiratoria por Pseudomonas aeruginosa en pacientes adultos en hospitalización a domicilio: caracterí sticas clínicas y evolutivas así como análisis de los factores pronósticos de recidiva

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 5, 2009, Pages 257-262

  Garde, Carmen ^a   Millet, Manuel ^a   Goenaga, Miguel Ángel ^a   Arzelus, Edurne ^a   Cuende, Ana ^a   Sarasqueta, Cristina ^b   Carrera, José Antonio ^a  

^a ACCURA UHD   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

Adultsb; Aeruginosa; Antibiotic; Athome; In; Infections; Outpatient; Parenteral; Pseudomonas; Respiratory; Therapy (OPAT) Hospital

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; PIPERAZINE; TAZOBACTAM; TOBRAMYCIN;

ADULT; AEROSOL; AGED; AIRWAY OBSTRUCTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE FREE INTERVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOME CARE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; REINFECTION; RESPIRATORY TRACT INFECTION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HOME CARE SERVICES, HOSPITAL-BASED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; RECURRENCE; RESPIRATORY TRACT INFECTIONS; TIME FACTORS;

EID: 67349174215     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2008.08.003     Document Type: Article

References (21)

1. D.R. Silver, I.L. Cohen, and P.F. Weinberg Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit Chest 101 1992 194 198
2. M.C. Pasteur, S.M. Helliwell, S.J. Houghton, S.C. Webb, J.E. Foweraker, and R.A. Coulden An investigation into causative factors in patients with bronchiectasis Am J Respir Crit Care Med 162 4 Pt 1 2000 1277 1284
3. P.L. Ho, K.N. Chan, M.S. Ip, W.K. Lam, C.S. Ho, and K.Y. Yuen The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis Chest 114 1998 Dec 1594 1598
4. A.F. Barker, L. Couch, S.B. Fiel, M.H. Gotfried, J. Ilowite, and K.C. Meyer Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis Am J Respir Crit Care Med 162 2 Pt 1 2000 481 485
5. L.A. Couch Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa Chest 120 3 Suppl 2001 114S 117S
6. S.M. Cheer, J. Waugh, and S. Noble Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis Drugs 63 2003 2501 2520
7. M.E. Hodson, C.G. Gallagher, and J.R. Govan A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur Respir J 20 2002 658 664
8. R.B. Moss Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Chest 121 2002 55 63
9. D. Weycker, J. Edelsberg, G. Oster, and G. Tino Prevalence and economic burden of bronchiectasis Clin Pulm Med 12 2005 205 209
10. M.A. Goenaga, C. Garde, M. Millet, and J.A. Carrera Parenteral antibiotic treatment and hospital based home care units. The current situation Enferm Infecc Microbiol Clin 18 2000 529
11. C. Garde, and M.A. Goenaga Outpatient intravenous antibiotic treatment Enferm Infecc Microbiol Clin 23 2005 393 395
12. J. Regalado, H. Mendoza, F. Aizpuru, E. Altuna, M. Gomez, and J.M. Cía Acute pyelonephritis treated under "home hospitalization." Ten years' experience] Enferm Infecc Microbiol Clin 24 2006 629 633
13. J.P. Horcajada, L. Garcia, N. Benito, C. Cervera, M. Sala, and A. Olivera Hospitalización a domicilio especializada en enfermedades infecciosas: experiencia de 1995 a 2002 Enferm Infecc Microbiol Clin 25 2007 429 436
14. Agustí-Vidal A, Rodríguez-Roisin R, García Navarro A, Estapé J, Guzman MC, Marin A, et al. Neumología. En: Farreras Rozman, editores. Medicina interna. Barcelona: Ediciones Doyma; 1992. p. 690.
15. S.D. Aaron, K.L. Vandemheen, W. Ferris, D. Fergusson, E. Tullis, and D. Haase Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled trial Lancet 2366 2005 463 471
16. D.S. Burgess Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections Clin Infect Dis 40 2005 S99 S104
17. S. Byrne, J. Maddison, P. Connor, I. Doughty, M. Dodd, and M. Jenney Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients J Antimicrob Chemother 36 Suppl A 1995 135 143
18. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. EBM Reviews-Cochrane Database of Systematic Reviews. 2006.
19. G. Doring, S.P. Conway, H.G. Heijerman, M.E. Hodson, N. Hoiby, and A. Smyth Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur Respir J 16 2000 749 767
20. U. Klettke, K. Magdorf, D. Staab, S. Bisson, K. Paul, and U. Wahn Ambulatory vs. inpatient intravenous antibiotic therapy in mucoviscidosis patients - a controlled study Pneumologie 53 1999 31 36
21. F. Laghzaoui, J. Murcia, P. Llorens, and J. Portilla Ceftazidima en infusión continua en el tratamiento de infecciones por Pseudomona aeruginosa en una unidad de hospitalización a domicilio Enferm Infecc Microbiol Clin 25 2007 71 72